文献速递浆细胞疾病造血干细胞移植与细胞治疗

新药时代不同诱导方案对骨髓瘤自体干细胞动员的影响

[Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该回顾性研究纳入140例新诊断多发性骨髓瘤患者,比较V、VR、DVR三种诱导方案对自体造血干细胞动员采集的影响。结果显示含来那度胺和达雷妥尤单抗方案降低采集成功率与优良率,而根据采集前1天CD34(+)细胞计数及时使用普乐沙福可改善采集结局。

要点

  • 含来那度胺≥2周期降低采集成功率,含达雷妥尤单抗≥2周期降低采集优良率。
  • 动员前血小板≥150×10(9)/L及采集前1天CD34(+)≥2个/μl预测采集成功。
  • 根据采集前1天CD34(+)计数及时加用普乐沙福可提高采集成功率与优良率。

核心结论

  • 新药时代不同诱导化疗方案对造血干细胞动员采集有明显影响,来那度胺和达雷妥尤单抗影响较大。
  • 根据采集前1天CD34(+)细胞计数及时予普乐沙福抢救动员可提高采集成功率和优良率。

研究设计与样本

  • 回顾性分析2022年11月至2024年11月上海交通大学医学院附属瑞金医院140例新诊断多发性骨髓瘤患者。
  • 按诱导方案分为V组37例、VR组28例、DVR组75例,比较动员与采集结局。

主要发现

  • V、VR、DVR组单次采集成功率分别为94.6%、82.1%、73.3%(P<0.05)。
  • V、VR、DVR组单次采集优良率分别为70.3%、50.0%、36.0%(P<0.01)。
  • 来那度胺应用≥2周期是采集成功率的不良因素(OR=0.25,95%CI:0.08~0.78,P<0.05)。
  • 达雷妥尤单抗应用≥2周期是采集优良率的不良因素(OR=0.40,95%CI:0.20~0.82,P<0.05)。

关键数值与推荐

  • 动员前血小板≥150×10(9)/L预测采集成功(OR=7.89,95%CI:2.43~25.62,P<0.001)。
  • 采集前1天CD34(+)≥2个/μl预测采集成功(OR=14.85,95%CI:4.67~47.16,P<0.001)。
  • 动员前白细胞≥4.5×10(9)/L预测采集优良(OR=2.35,95%CI:1.01~5.45,P=0.046)。
  • 动员前血小板≥150×10(9)/L预测采集优良(OR=5.85,95%CI:1.72~19.94,P=0.005)。
  • 采集前1天CD34(+)≥10个/μl预测采集优良(OR=10.45,95%CI:4.26~25.63,P<0.001)。

临床怎么用

  • 对含来那度胺或达雷妥尤单抗≥2周期的患者应提前评估动员风险并优化采集策略。
  • 可根据采集前1天CD34(+)细胞计数及时加用普乐沙福进行抢救动员。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to retrospectively analyze the impact of different induction regimens on autologous hematopoietic stem cell mobilization in the peripheral blood of patients with multiple myeloma in the new drug era. Methods: This study retrospectively analyzed the data of 140 patients with newly diagnosed multiple myeloma who underwent autologous hematopoietic stem cell mobilization at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from November 2022 to November 2024. The patients were categorized based on their treatment regimens into the bortezomib-based group (V, 37 cases), bortezomib + lenalidomide-based group (VR, 28 cases), and daratumumab + bortezomib + lenalidomide-based group (DVR, 75 cases). The study compared the effects of different induction chemotherapy regimens in terms of hematopoietic stem cell mobilization, collection success rate, and quality rate. Results Among the 140 patients, 73 were males and 67 were females, and the median age was 58 (range, 34-71) years. The success rates of first-time hematopoietic stem cell collection were 94.6%, 82.1%, and 73.3% in the V, VR, and DVR groups, respectively (P<0.05). The quality rates of first-time hematopoietic stem cell collection were 70.3%, 50.0%, and 36.0% in the V, VR, and DVR groups, respectively (P<0.01). Multivariate logistic regression analysis revealed that lenalidomide use for ≥2 cycles was an adverse factor affecting collection success (OR=0.25, 95% CI: 0.08-0.78, P<0.05), whereas daratumumab use for ≥2 cycles was an adverse factor for collection quality (OR=0.40, 95% CI: 0.20-0.82, P<0.05). A premobilization platelet count ≥150×10(9)/L (OR=7.89, 95% CI: 2.43-25.62, P<0.001) and a CD34(+) cell count of ≥2/μl on the day before collection (OR=14.85, 95% CI: 4.67-47.16, P<0.001) were considered independent predictors of successful collection. A premobilization white blood cell count of ≥4.5×10(9)/L (OR=2.35, 95% CI: 1.01-5.45, P=0.046), a premobilization platelet count of ≥150×10(9)/L (OR=5.85, 95% CI: 1.72-19.94, P<0.005), and a CD34(+) cell count of ≥10/μl on the day before collection (OR=10.45, 95% CI: 4.26-25.63, P<0.001) were considered independent predictors for collection quality. Timely administration of plerixafor based on the CD34(+) cell count on the day before collection improved the success rate by 27.8% and the quality rate by 5.0% . Conclusion: In the new drug era, different induction chemotherapy regimens significantly impact hematopoietic stem cell mobilization and collection, with lenalidomide and daratumumab exhibiting notable effects. Timely administration of plerixafor for salvage mobilization based on CD34(+) cell counts on the day before collection improves both the success rate and quality rate of hematopoietic stem cell collection. 目的: 回顾性分析新药时代不同诱导方案对多发性骨髓瘤患者外周血自体造血干细胞动员的影响。 方法: 回顾性收集2022年11月至2024年11月在上海交通大学医学院附属瑞金医院进行自体造血干细胞动员的新诊断多发性骨髓瘤患者140例,根据患者的用药情况将其分为三组:以硼替佐米为基础方案(V)组37例、以硼替佐米+来那度胺为基础方案(VR)组28例、以达雷妥尤单抗+硼替佐米+来那度胺为基础方案(DVR)组75例。比较不同诱导化疗方案对造血干细胞动员、采集成功率、优良率的影响。 结果: 140例患者中男73例,女67例,中位年龄58(34~71)岁,V组、VR组、DVR组单次造血干细胞采集成功率分别为94.6%、82.1%、73.3%(P<0.05),单次造血干细胞采集优良率分别为70.3%、50.0%、36.0%(P<0.01)。多因素Logistic回归分析显示,来那度胺应用≥2个周期是影响造血干细胞动员采集成功率的不良因素(OR=0.25,95%CI:0.08~0.78,P<0.05);达雷妥尤单抗应用≥2个周期是影响造血干细胞动员采集优良率的不良因素(OR=0.40,95% CI:0.20~0.82,P<0.05)。动员前血小板计数≥150×10(9)/L(OR=7.89,95%CI:2.43~25.62,P<0.001)、采集造血干细胞前1 d CD34(+)细胞计数≥2个/μl(OR=14.85,95%CI:4.67~47.16,P<0.001)为造血干细胞采集成功的独立预测因素;动员前白细胞计数≥4.5×10(9)/L(OR=2.35,95% CI:1.01~5.45,P=0.046)、动员前血小板计数≥150×10(9)/L(OR=5.85,95%CI:1.72~19.94,P=0.005)、采集造血干细胞前1 d CD34(+)细胞计数≥10个/μl为造血干细胞采集优良的独立预测因素(OR=10.45,95% CI:4.26~25.63,P<0.001)。根据采集造血干细胞前1 d外周血CD34(+)细胞计数及时加用普乐沙福抢救动员提高了27.8%的造血干细胞采集成功率和5.0%的优良率。 结论: 新药时代不同诱导化疗方案对造血干细胞的动员采集有明显影响,其中来那度胺和达雷妥尤单抗影响较大,根据采集前1 d的CD34(+)细胞计数及时予普乐沙福抢救动员可以提高造血干细胞采集的成功率和优良率。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang XL, Pan MM, Jin SW, et al. [Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41486659. doi:10.3760/cma.j.cn121090-20250221-00084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。